Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zai LabZLAB -0.32%69 3-Year Revenue Growth Rate is 23.20% as of Jun. 2026, which is 64% below its 10-year median of 63.60. GuruFocus rates ZLAB with a GF Score™ of 69/100 and a GF Value™ of $28.80 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 768 Biotechnology companies, Zai Lab ranks better than 74.22% on this metric.
During the past 12 months, Zai Lab's average Revenue per Share Growth Rate was -0.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 23.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 43.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 11 years, the highest 3-Year average Revenue per Share Growth Rate of Zai Lab was 818.90% per year. The lowest was 23.20% per year. And the median was 63.60% per year.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Zai Lab 3-Year Revenue Growth Rate Related Terms
ZLAB vs COAG, SLS, IOVA: 3-Year Revenue Growth Rate Comparison
For the Biotechnology subindustry, Zai Lab's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zai Lab 3-Year Revenue Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zai Lab's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Zai Lab's 3-Year Revenue Growth Rate falls into.
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of 23.20% mean?
Zai Lab (ZLAB) has a 3-Year Revenue Growth Rate of 23.20% as of Jun. 2026. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Zai Lab and its competitors. This is 64% below median its historical median of 63.60. Over the past decade, Zai Lab's 3-Year Revenue Growth Rate has ranged from 23.20 to 818.90. According to the industry distribution chart, Zai Lab ranks #198 out of 768 companies in the Biotechnology industry, placing it in the top 25.8%.
Is Zai Lab's 3-Year Revenue Growth Rate too high?
Zai Lab's current 3-Year Revenue Growth Rate of 23.20% is 64% below median its 10-year median of 63.60. Over the past 10 years, this metric has ranged from a low of 23.20 to a high of 818.90. The Biotechnology industry median 3-Year Revenue Growth Rate is 2.95. Zai Lab's value of 23.20% is 686.4% above this industry median. Based on the distribution chart, Zai Lab ranks #198 out of 768 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zai Lab has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zai Lab's 3-Year Revenue Growth Rate compare to COAG and SLS?
According to the Biotechnology industry distribution chart, Zai Lab ranks #198 out of 768 companies for 3-Year Revenue Growth Rate. This puts Zai Lab in the upper half of its industry. The industry median 3-Year Revenue Growth Rate is 2.95. Zai Lab's value of 23.20% is 686.4% above this benchmark. Historically, Zai Lab's own 3-Year Revenue Growth Rate has ranged from 23.20 to 818.90 over the past decade. While the company's 10-year median is 63.60 vs. the industry median of 2.95, Zai Lab has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Biotechnology company?
The median 3-Year Revenue Growth Rate among Biotechnology companies is 2.95, based on 768 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zai Lab's current 3-Year Revenue Growth Rate of 23.20% is 686.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Zai Lab and its competitors. For the Biotechnology industry, the median 3-Year Revenue Growth Rate is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zai Lab's current 3-Year Revenue Growth Rate is 23.20%, which is 64% below median its own 10-year median of 63.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zai Lab stock overvalued right now?
Based on GuruFocus' analysis, Zai Lab (ZLAB) is currently considered Modestly Undervalued. The stock's GF Value™ is $28.80, compared to a current price of $25.90 — trading 10.1% below its estimated fair value. The current 3-Year Revenue Growth Rate is 23.20%, which is 64% below median its 10-year median of 63.60 and 686.4% above the Biotechnology industry median of 2.95. Zai Lab's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For Zai Lab (ZLAB), the current 3-Year Revenue Growth Rate is 23.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zai Lab (ZLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued.
The current stock price of $25.90 is trading 10.1% below its estimated GF Value™ of $28.80.
GuruFocus considers Zai Lab to be Modestly Undervalued.
Key valuation signals for ZLAB:
3-Year Revenue Growth Rate: 23.20% (64% below median its 10-year median of 63.60)
GF Value™: $28.80 vs. price of $25.90 (10.1% below fair value)
Industry Position: 686.4% above the Biotechnology median (#198 of 768)
No single metric tells the full story. See the ZLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
69GF Score
Get the complete analysis for ZLAB
3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLAB has been successfully added to your 
